Literature DB >> 33823854

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma.

Francesca Reggiani1, Elisabetta Sauta1,2, Federica Torricelli1, Eleonora Zanetti3, Elena Tagliavini3, Giacomo Santandrea3,4, Giulia Gobbi1, Giovanna Damia5, Riccardo Bellazzi2, Davide Ambrosetti6, Alessia Ciarrocchi1, Valentina Sancisi7.   

Abstract

Entities:  

Keywords:  CRISPR/Cas9 screening; EGLN1; HIF1A; KRAS; Lung cancer

Year:  2021        PMID： 33823854     DOI： 10.1186/s12943-021-01357-z

Source DB:  PubMed          Journal:  Mol Cancer        ISSN： 1476-4598            Impact factor:   27.401


× No keyword cloud information.
  13 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Authors:  Matthew P Patricelli; Matthew R Janes; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Linda V Kessler; Yuching Chen; Jeff M Kucharski; Jun Feng; Tess Ely; Jeffrey H Chen; Sarah J Firdaus; Anjali Babbar; Pingda Ren; Yi Liu
Journal:  Cancer Discov       Date:  2016-01-06       Impact factor: 39.397

3.  Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

Authors:  Colles Price; Stanley Gill; Zandra V Ho; Shawn M Davidson; Erin Merkel; James M McFarland; Lisa Leung; Andrew Tang; Maria Kost-Alimova; Aviad Tsherniak; Oliver Jonas; Francisca Vazquez; William C Hahn
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

4.  Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.

Authors:  Haiwei Mou; Jill Moore; Sunil K Malonia; Yingxiang Li; Deniz M Ozata; Soren Hough; Chun-Qing Song; Jordan L Smith; Andrew Fischer; Zhiping Weng; Michael R Green; Wen Xue
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

5.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Authors:  Marta Puyol; Alberto Martín; Pierre Dubus; Francisca Mulero; Pilar Pizcueta; Gulfaraz Khan; Carmen Guerra; David Santamaría; Mariano Barbacid
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

6.  Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

Authors:  Cheng-Qiong Mao; Meng-Hua Xiong; Yang Liu; Song Shen; Xiao-Jiao Du; Xian-Zhu Yang; Shuang Dou; Pei-Zhuo Zhang; Jun Wang
Journal:  Mol Ther       Date:  2014-02-05       Impact factor: 11.454

7.  Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.

Authors:  Robin M Meyers; Jordan G Bryan; James M McFarland; Barbara A Weir; Ann E Sizemore; Han Xu; Neekesh V Dharia; Phillip G Montgomery; Glenn S Cowley; Sasha Pantel; Amy Goodale; Yenarae Lee; Levi D Ali; Guozhi Jiang; Rakela Lubonja; William F Harrington; Matthew Strickland; Ting Wu; Derek C Hawes; Victor A Zhivich; Meghan R Wyatt; Zohra Kalani; Jaime J Chang; Michael Okamoto; Kimberly Stegmaier; Todd R Golub; Jesse S Boehm; Francisca Vazquez; David E Root; William C Hahn; Aviad Tsherniak
Journal:  Nat Genet       Date:  2017-10-30       Impact factor: 38.330

Review 8.  Changing paradigm in advanced and metastatic non-small cell lung cancer.

Authors:  Dipesh Uprety; Kaushal Parikh; Anita Sawkar; Anastasios Dimou; Konstantinos Leventakos
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

9.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Authors:  David S Hong; Marwan G Fakih; John H Strickler; Jayesh Desai; Gregory A Durm; Geoffrey I Shapiro; Gerald S Falchook; Timothy J Price; Adrian Sacher; Crystal S Denlinger; Yung-Jue Bang; Grace K Dy; John C Krauss; Yasutoshi Kuboki; James C Kuo; Andrew L Coveler; Keunchil Park; Tae Won Kim; Fabrice Barlesi; Pamela N Munster; Suresh S Ramalingam; Timothy F Burns; Funda Meric-Bernstam; Haby Henary; Jude Ngang; Gataree Ngarmchamnanrith; June Kim; Brett E Houk; Jude Canon; J Russell Lipford; Gregory Friberg; Piro Lito; Ramaswamy Govindan; Bob T Li
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 176.079

10.  DGIdb 3.0: a redesign and expansion of the drug-gene interaction database.

Authors:  Kelsy C Cotto; Alex H Wagner; Yang-Yang Feng; Susanna Kiwala; Adam C Coffman; Gregory Spies; Alex Wollam; Nicholas C Spies; Obi L Griffith; Malachi Griffith
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971
View more
  4 in total

Review 1.  The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.

Authors:  Silvia Strocchi; Francesca Reggiani; Giulia Gobbi; Alessia Ciarrocchi; Valentina Sancisi
Journal:  Oncogene       Date:  2022-06-15       Impact factor: 8.756

2.  Construction of a Novel Ferroptosis-Related Gene Signature for Predicting Survival of Patients With Lung Adenocarcinoma.

Authors:  Xiaojie Song; Liqun Wu; Guangqiang Wang; Baoyi Liu; Wenyong Zhu
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

Review 3.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.

Authors:  Christophe Bontoux; Véronique Hofman; Patrick Brest; Marius Ilié; Baharia Mograbi; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

4.  KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM).

Authors:  Eugenia Lorenzini; Federica Torricelli; Raffaella Zamponi; Benedetta Donati; Veronica Manicardi; Elisabetta Sauta; Italo Faria do Valle; Francesca Reggiani; Mila Gugnoni; Gloria Manzotti; Valentina Fragliasso; Emanuele Vitale; Simonetta Piana; Valentina Sancisi; Alessia Ciarrocchi
Journal:  NAR Cancer       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.